Core Viewpoint - Yifan Pharmaceutical's product Yinikang (Dinggan Cross-linked Sodium Hyaluronate Injection) is in a rapid growth phase, with significant market potential in the treatment of osteoarthritis, particularly among the aging population in China [1][2] Group 1: Product Development and Market Position - Yifan Pharmaceutical has obtained exclusive import and distribution rights for Yinikang in China and Australia, and the product received its drug registration certificate in April 2023, allowing for official sales in China [1] - The product is expected to be included in the new national medical insurance directory by December 2023, enhancing accessibility and affordability of innovative drugs [1] - The market for osteoarthritis treatment in China is projected to reach between 102 billion to 170 billion RMB, indicating substantial growth potential for Yifan's Yinikang product [2] Group 2: Financial Performance and Growth Strategy - Yifan Pharmaceutical achieved a revenue of 5.16 billion RMB in 2024, marking a year-on-year growth of 26.84%, with domestic revenue at 3.85 billion RMB (up 34.88%) and international revenue at 1.31 billion RMB (up 7.87%) [4] - The company is focusing on internationalization, having successfully entered the EU market with its Amikacin Sulfate Injection, marking a significant milestone in its global strategy [5] - Yifan aims to increase the number of major products generating over 10 million RMB in annual sales from 29 to 35 by 2025, with specific targets for products exceeding 50 million and 100 million RMB [7] Group 3: Competitive Advantages and Future Outlook - Yifan Pharmaceutical has established a comprehensive production and sales network, positioning itself as one of the few domestic companies with a complete closed-loop capability in the pharmaceutical industry [3] - The company emphasizes innovation and internationalization as core strategies, leveraging its experience in clinical trials and regulatory processes to enhance its product line and market competitiveness [6][7] - With ongoing innovation and market expansion, Yifan is expected to achieve continuous breakthroughs in both domestic and international pharmaceutical markets [7]

因此，靶向铁死亡来抑制肿瘤进展仍是一项挑战，开发能够作用于多条通路从而提高治疗效果的诱导铁死亡药物至关重要。 2025 年 7 月 7 日 ，上海中医药大学 刘三宏 研究员、海军军医大学 张卫东 教授、上海中医药大学 王群 副研究员、 北京中医药大学东直门医院 林生 研究员等 在 Signal Transduction and Targeted Therapy 期刊发表 了题为： Acevaltrate as a novel ferroptosis inducer with dual targets of PCBP1/2 and GPX4 in colorectal cancer 的研究论文。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 在过去的十年里， 铁死亡 （ ferroptosis ） 已被广泛认可为一种新兴的抗肿瘤治疗策略。与 caspase-3 诱导的细胞凋亡和 RIPK3 诱导的程序性坏死不同，铁死 亡依赖于不受限制的脂质过氧化。细胞内亚铁离子 （Fe 2+ ） 和活性氧 （ROS） 的高水平是铁死亡与其他细胞死亡形式的区别特征之一，它们不仅维持着肿瘤 细胞的增殖，还导致膜磷脂的脂质过氧化。因此，亚 ...

Core Viewpoint - The article narrates the journey of a family dealing with a cancer diagnosis, highlighting the emotional and medical challenges faced by the family as they seek treatment options for the mother diagnosed with duodenal adenocarcinoma and multiple liver metastases. Group 1: Diagnosis and Initial Findings - The mother, previously healthy, was diagnosed with duodenal adenocarcinoma with multiple liver metastases after a routine health check-up revealed a 4.7 cm lesion on the liver [4][5][8] - Initial assessments indicated no surgical options available due to the extent of the disease [4][10] Group 2: Diagnostic Journey - The family sought further evaluations, leading to a series of tests including ultrasound and MRI, which confirmed the presence of malignant lesions [6][8][20] - Tumor markers showed elevated CA199 levels at 736, indicating a poor prognosis [7][8] Group 3: Treatment Options and Decisions - The family explored treatment options, including participation in clinical trials for chemotherapy and targeted therapy [14][27] - The mother expressed a desire for a PET CT scan to assess the extent of metastasis, which revealed a primary tumor in the duodenum with liver metastases [17][19] Group 4: Pathological Confirmation - Biopsy results confirmed the diagnosis of duodenal cancer with liver metastases, leading to a revised treatment plan [22][25] Group 5: Treatment Strategy - The treatment plan included a combination of chemotherapy and targeted therapy, with the potential for surgery if the tumor responded well [27][28] - The family joined a support group that provided valuable information and emotional support during the treatment process [28][29] Group 6: Surgical Considerations - After successful chemotherapy, the mother was evaluated for surgical options, with a focus on minimizing risks associated with the complex surgery [39][56] - The surgical team emphasized the importance of thorough imaging to guide the surgical approach, leading to a decision to proceed with surgery [49][50] Group 7: Surgical Outcome - The surgery was successful, with the removal of both the primary tumor and liver metastases, and pathology indicated no active disease in the liver [59][60] - Post-operative recovery was complicated by fever and other issues, but the medical team remained optimistic about the mother's recovery [67][70]